An observational study in Ovarian Cancer and Genetic Predisposition to Disease, sponsored by Abramson Cancer Center at Penn Medicine. Recruiting at 1 site in United States. Open to female participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Abramson Cancer Center at Penn Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine — 4 open to participants now, 4 under way, none of them phase 3. Ovarian Neoplasms · Abramson Cancer Center at Penn Medicine.
Among the 15 studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine, this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 13th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →4 of the 15 studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 25+ · Women only · Healthy volunteers
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 30 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 1
First in 2007; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 28 across the 10 interventional studies, 50 across the 5 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Abramson Cancer Center at Penn Medicine is the lead sponsor of 462 studies on the registry; 88 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.
3 of the studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962059Abramson Cancer Center at Penn MedicineHealthy Volunteers Study | 2027-01-15 |
| NCT07915336Abramson Cancer Center at Penn MedicinePeer Ambassador in Gyn Onc Trials | 2027-09-30 |
| NCT06436248Abramson Cancer Center at Penn MedicinePolygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the role of the bacterial environments and metabolites in the early detection and prediction of ovarian cancer development. Vaginal swabs and stool samples will be collected from healthy volunteers, or those without a known ovarian cancer diagnosis or genetic ovarian cancer risk. These samples will be compared to samples from participants with increased cancer risk and ovarian cancer diagnoses.
This study will examine the role of the microbiome and its metabolites in early detection and prediction of ovarian cancer development. It has been previously shown that the composition and function of the microbiome may play a role in the development and progression of several types of cancer. One proposed mechanism by which the microbiome may contribute to cancer development is through the production of certain metabolic byproducts. Such metabolites produced or modified by the microbiome have emerged as a prominent factor with potential local and systemic effects on the host, and were proposed to mediate the microbiome's contribution to cancer development. Microbial metabolites can promote cancer development by activating signaling pathways that promote cell growth and survival. In addition, the microbiota affects carcinogenesis through the release of carcinogenic molecules, such as genotoxins, and through the production of tumor-promoting metabolites. Furthermore, microbial metabolites have been studied as potential biomarkers for cancer, with some research suggesting that certain microbial metabolites may be able to distinguish between healthy individuals and those with cancer. The microbiome of the female reproductive tract is relatively understudied compared to the gut microbiome, but recent studies have shown that it is present and diverse in various parts of the reproductive tract such as the vagina, cervix, and fallopian tubes. however, a microbiome or metabolome signature predictive of ovarian cancer has not yet been established. Eligible individuals will be consented to provide a one-time, self-administered vaginal swab sample and stool sample. Clinical research assistants/coordinators, genetic counselors, and/or study physicians will consent patients and process and store the samples of consented participants. Participants will be provided a stool collection kit at the time of consent with instructions for providing the sample and sending it back to the laboratory.
Eligible participants will be patients of the Cancer Risk Evaluation Program at the Abramson Cancer Center. Patients who meet the above criteria will be approached to participate as healthy volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Females 30 or older who do not have a genetic predisposition to ovarian cancer, are unaffected by cancer, and have not had bilateral oophorectomy.
Other: Self-Administered Sample Collection
Participants will collect vaginal swabs and a stool sample.
Microbiome Involvement
Investigate the involvement of the microbiome and associated metabolites in ovarian cancer.
Time frame: One-time sample donation of vaginal swabs collected at the time of the patient's appointment. A subsequent stool sample will be provided within a week of the vaginal swab.
Predictive Model
Generate a predictive model for ovarian cancer risk and progression. Healthy volunteers will provide a control group to compare to BRCA-carrier and affected cohorts consented through the CREP Biobank study in order to mechanistically understand the function of the identified metabolites in disease prevention, initiation, progression, and treatment response.
Time frame: One-time sample donation of vaginal swabs collected at the time of the patient's appointment. A subsequent stool sample will be provided within a week of the vaginal swab.
Plan to share: Yes — Deidentified data of patients samples, survey answers, and complementary medical information will be shared with investigators at Stanford and Columbia. This information will be used to identify factors for analysis such as prescribed medications, treatment types and timeframes, among others.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be shared with investigators three months after enrollment is complete. This should provide time for enrolled subjects to complete participation, ensure all data entry is complete, and that all data from records is obtained.
Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine →